MedTrace Logo

Capecitabine as NeoAdjuvant Therapy in Locally Advanced Breast Cancer

NCT00347438 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2015-12-14

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and effectiveness of capecitabine before surgery.

The study will also help gain more information about the effects of the capecitabine on physical and emotional well-being and how well the participants on capecitabine follow the study drug plan.

Conditions

Interventions

DRUG

Capecitabine

Capecitabine twice daily for 14 days followed by 7 days without taking drug (1 cycle). This schedule is followed for 8 cycles (about 24 weeks).

Sponsors & Collaborators

  • Breast Cancer Research Foundation

    collaborator OTHER

  • Roche Pharma AG

    collaborator INDUSTRY

  • University of Chicago

    lead OTHER

Principal Investigators

  • Olufunmilayo I Olopade, MD · University of Chicago

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Primary Completion
2013-03-31
Completion
2013-03-31

Countries

  • United States
  • Nigeria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00347438 on ClinicalTrials.gov